Trial
NCT04419181
Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Rochester
Collaborators
—
Condition
HER2-positive Breast Cancer
Intervention
Docetaxel
Why stopped
Change in the landscape of current treatment of early stage breast cancer. Larger clinical trials answering similar questions are expected to result in the next few years.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-14